Ozempic is covered by most insurance plans when prescribed for type 2 diabetes, its FDA-approved use. If you’re hoping to use it for weight loss, coverage becomes much less likely. Most insurers will not pay for Ozempic unless you have a type 2 diabetes diagnosis, and some employers exclude GLP-1 drugs from their health plans entirely.
The reality is that your coverage depends on why you’re taking it, what type of insurance you have, and whether your plan includes GLP-1 medications on its formulary.
Coverage for Type 2 Diabetes
Ozempic (semaglutide) is FDA-approved specifically for managing type 2 diabetes alongside diet and exercise. When your doctor prescribes it for this purpose, most commercial insurance plans cover it, though many require prior authorization first. That means your insurer needs to approve the prescription before your pharmacy can fill it, a process that can take a few days to a couple of weeks. Your plan’s formulary determines which tier Ozempic falls into, and that tier sets your copay. Even with coverage, you could still face significant out-of-pocket costs depending on your plan’s structure.
Coverage for Weight Loss
Ozempic is not FDA-approved for weight loss. While doctors can and do prescribe it off-label for obesity, insurers typically won’t cover it without a type 2 diabetes diagnosis. Having a high BMI alone usually isn’t enough. Some plans may cover it if you have an obesity-related condition like high cholesterol or high blood pressure, but this varies widely.
If weight loss is your primary goal, the branded version of semaglutide approved for that purpose is Wegovy, not Ozempic. Wegovy also received FDA approval to reduce the risk of heart attack, stroke, and cardiovascular death in adults who have heart disease along with obesity or overweight. That cardiovascular indication has opened a second pathway to coverage for some patients, though it applies to Wegovy specifically.
Employer-Sponsored Plans
If you get insurance through your job, coverage for GLP-1 drugs used for weight loss is expanding but still uncommon. In 2025, only 19 percent of large employers covered GLP-1 medications when prescribed primarily for weight loss. The bigger the company, the better your odds: 43 percent of firms with 5,000 or more workers offered this coverage, compared to just 16 percent of firms with 200 to 999 workers. Some employers have gone the opposite direction, explicitly excluding GLP-1 drugs from their plans to control costs. Your HR department or benefits summary can tell you where your plan stands.
Medicare and Medicaid
Medicare Part D covers Ozempic for type 2 diabetes, but it has historically excluded coverage for drugs used purely for weight loss. That’s changing in a limited way. Starting July 2026, the Medicare GLP-1 Bridge program will provide eligible beneficiaries with access to certain GLP-1 drugs for weight reduction through the end of 2027. This is a temporary demonstration program, not a permanent benefit.
To qualify for the Bridge program for weight loss purposes, you’ll need prior authorization from a provider confirming you meet specific criteria. The thresholds depend on your BMI and whether you have certain related conditions:
- BMI of 35 or higher: You may qualify with no additional diagnosis required.
- BMI of 30 or higher: You may qualify if you also have heart failure with preserved ejection fraction, uncontrolled high blood pressure despite taking two medications, or chronic kidney disease stage 3a or above.
- BMI of 27 or higher: You may qualify if you also have pre-diabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.
If your doctor prescribes an eligible GLP-1 drug for a use already coverable under standard Part D (such as Wegovy for cardiovascular risk reduction), you wouldn’t go through the Bridge program. Your Part D plan would handle that through its normal formulary and exceptions process.
Medicaid coverage for Ozempic varies by state. Each state’s Medicaid program sets its own formulary and prior authorization rules.
Savings Cards and Patient Assistance
Novo Nordisk, Ozempic’s manufacturer, offers a savings card for people with commercial insurance. This can reduce your copay, sometimes significantly. However, you’re not eligible if you have Medicare or Medicaid. The savings card is designed to supplement private insurance, not replace it.
If you don’t have insurance at all, the list price of Ozempic can run over $900 per month. Some patients turn to manufacturer patient assistance programs, pharmacy discount programs, or compounded versions of semaglutide to bring costs down, though compounded versions come with their own quality and safety considerations.
What to Do If You’re Denied
Insurance denials for Ozempic are common, especially when the insurer questions whether the drug is medically necessary for your situation. A denial isn’t the final word. You have the right to appeal, and partnering with your doctor’s office makes a significant difference in the outcome.
A strong appeal typically includes a letter of medical necessity from your doctor explaining why Ozempic is the right treatment for you, along with supporting lab results, test data, and references to clinical guidelines or peer-reviewed research backing the recommendation. Your doctor can also request a peer-to-peer evaluation, which is a phone call between your physician and a doctor at the insurance company to discuss the medical rationale directly. This step alone resolves many first-level appeals.
The most common reasons for denial are that the insurer considers the treatment not medically necessary or views it as experimental for your particular use. In either case, concrete clinical data showing how the medication is improving your health (or why alternatives haven’t worked) strengthens your case considerably. If your first appeal fails, most plans offer at least one additional level of internal review, and you can pursue an external review after that.